ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Accepts Pegvaliase BLA, Grants Priority Review Designation
pharmaceutical-technology
August 31, 2017BioMarin announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme product, to reduce blood phenylalanine (Phe)
Pharma Sources Insight July 2025
